Loss of calbindin-D28K is associated with the full range of tangle pathology within basal forebrain cholinergic neurons in Alzheimer's disease

Abstract Basal forebrain cholinergic neurons (BFCN) are selectively vulnerable in Alzheimer's disease (AD). We have shown that most of the BFCN in the human brain contain the calcium-binding protein calbindin-D28K (CB), a large proportion lose their CB in the course of normal aging, and the BFC...

Full description

Saved in:
Bibliographic Details
Published inNeurobiology of aging Vol. 36; no. 12; pp. 3163 - 3170
Main Authors Ahmadian, Saman S, Rezvanian, Aras, Peterson, Melanie, Weintraub, Sandra, Bigio, Eileen H, Mesulam, Marek-Marsel, Geula, Changiz
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Basal forebrain cholinergic neurons (BFCN) are selectively vulnerable in Alzheimer's disease (AD). We have shown that most of the BFCN in the human brain contain the calcium-binding protein calbindin-D28K (CB), a large proportion lose their CB in the course of normal aging, and the BFCN which degenerate in AD lack CB. Here, we investigated the relationship between CB in the BFCN and the process of tangle formation in AD using antibodies to tau epitopes that appear early, intermediate or late in the process of tangle formation. Very small percentages (0%–3.7%) of CB-positive BFCN contained pretangles and/or tangles, and very small percentages (0%–5%) of the total BFCN pretangles and/or tangles were in CB-immunoreactive neurons. The number of CB-positive BFCN which contained tau immunoreactivity was highest for the early epitope and lower for intermediate epitopes. A late appearing epitope was absent from CB-positive BFCN. Age-related loss of CB appears to coincide with tangle formation in the BFCN and is associated with the full range of tau pathology, including late appearing epitopes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2015.09.001